循环生物标志物(肾上腺髓质素原、TNFR1和NT-proBNP)与2型糖尿病患者肾功能下降的关联:一项法国前瞻性队列研究
该法国前瞻性队列纳入1135例2型糖尿病患者,评估MR-proADM、sTNFR1和NT-proBNP对肾功能下降(RFL)和快速肾功能下降(RRFD)的预测价值。三种标志物均独立预测RFL和RRFD,联合应用可提高判别能力。
要点
- MR-proADM、sTNFR1和NT-proBNP各自独立预测RFL和RRFD。
- 三种标志物联合应用对RFL和RRFD的判别能力最高。
- 在既定危险因素基础上,联合标志物改善肾功能丧失的风险预测。
核心结论
- 在既定危险因素之外,MR-proADM、sTNFR1和NT-proBNP改善2型糖尿病患者肾功能丧失的风险预测。
研究设计与样本
- 法国前瞻性队列研究,纳入1135例2型糖尿病患者,平均eGFR 76 mL/min,中位uACR 2.6 mg/mmol,中位GFR斜率-1.6 mL/min/年。
主要发现
- 随访期间397例发生RFL,233例发生RRFD,292例死亡。
- MR-proADM、sTNFR1和NT-proBNP联合预测RFL的校正风险比分别为1.59(95%CI 1.34-1.89,P<0.0001)、1.33(95%CI 1.14-1.55,P=0.0003)和1.22(95%CI 1.07-1.40,P=0.004)。
- MR-proADM、sTNFR1和NT-proBNP联合预测RRFD的校正比值比分别为1.56(95%CI 1.7-2.09,P=0.003)、1.72(95%CI 1.33-2.22,P<0.0001)和1.28(95%CI 1.03-1.59,P=0.02)。
- 三种标志物联合对RFL的C统计量差值分别为0.054(P<0.0001)和0.067(P<0.0001),对RRFD的C统计量差值为0.027(P<0.0001)。
关键数值与推荐
- RFL定义为eGFR较基线下降≥40%;RRFD定义为绝对年eGFR斜率<-5 mL/min/年。
- 调整因素包括年龄、性别、糖尿病病程、HbA1c、血压、基线eGFR和uACR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We explored the prognostic value of three circulating candidate biomarkers-midregional-proadrenomedullin (MR-proADM), soluble tumor necrosis factor receptor 1 (sTNFR1), and N-terminal prohormone brain natriuretic peptide (NT-proBNP)-for change in renal function in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Outcomes were defined as renal function loss (RFL), ≥40% decline of estimated glomerular filtration rate (eGFR) from baseline, and rapid renal function decline (RRFD), absolute annual eGFR slope <-5 mL/min/year. We used a proportional hazard model for RFL and a logistic model for RRFD. Adjustments were performed for established risk factors (age, sex, diabetes duration, HbA1c, blood pressure, baseline eGFR, and urinary albumin-to-creatinine ratio [uACR]). C-statistics were used to assess the incremental predictive value of the biomarkers to these risk factors. RESULTS: Among 1,135 participants (mean eGFR 76 mL/min, median uACR 2.6 mg/mmol, and median GFR slope -1.6 mL/min/year), RFL occurred in 397, RRFD developed in 233, and 292 died during follow-up. Each biomarker predicted RFL and RRFD. When combined, MR-proADM, sTNFR1, and NT-proBNP predicted RFL independently from the established risk factors (adjusted hazard ratio 1.59 [95% CI 1.34-1.89], P < 0.0001; 1.33 [1.14-1.55], P = 0.0003; and 1.22 [1.07-1.40], P = 0.004, respectively) and RRFD (adjusted odds ratio 1.56 [95% CI 1.7-2.09], P = 0.003; 1.72 [1.33-2.22], P < 0.0001; and 1.28 [1.03-1.59], P = 0.02, respectively). The combination of the three biomarkers yielded the highest discrimination (difference in C-statistic = 0.054, P < 0.0001; 0.067, P < 0.0001 for RFL; and 0.027, P < 0.0001 for RRFD). CONCLUSIONS: In addition to established risk factors, MR-proADM, sTNFR1, and NT-proBNP improve risk prediction of loss of renal function in patients with type 2 diabetes.
引用
- Saulnier PJ, Gand E, Velho G, et al. Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. Diabetes Care. 2016. PMID: 27998909. doi:10.2337/dc16-1571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。